Zealand Pharma A/S (OTCMKTS:ZLDPF) Sets New 12-Month Low – What’s Next?

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) hit a new 52-week low on Monday. The stock traded as low as $33.08 and last traded at $33.08, with a volume of 358 shares traded. The stock had previously closed at $33.88.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Jefferies Financial Group cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Barclays cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 8th. Finally, Zacks Research upgraded shares of Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 12th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, Zealand Pharma A/S currently has an average rating of “Hold”.

Zealand Pharma A/S Stock Performance

The company has a market cap of $2.37 billion, a price-to-earnings ratio of 5.49 and a beta of 0.95. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.98 and a current ratio of 13.98. The company has a fifty day moving average of $42.68 and a two-hundred day moving average of $45.52.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. Its research is primarily directed toward metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs, often using innovative peptide structures and delivery approaches.

Zealand’s portfolio has included dasiglucagon, a glucagon analogue developed for the treatment of severe hypoglycemia.